histologic transformation; non-Hodgkin's lymphoma; stem cell transplantation Among the early descriptions of transformation of lymphoma were reports by Gall in 1942 and Rappaport in 1956 . 1, 2 Despite attempts to further characterize histologic transformation (HT), there is still much uncertainty as to what constitutes transformation, its true incidence, risk factors for transformation, and optimal treatment.
Definition of HT
How does one approach transformed lymphoma? The difficulty in this task arises foremost in the lack of a uniform definition. Clinical studies utilize varied definitions of HT for inclusion criteria based on the classification system of the time, whether Rappaport, Working Formulation, Revised European-American Lymphoma (REAL), or the current World Health Organization (WHO) 3 (Table 1) . Readdressing the observations originally made by Rappaport helps to clarify what comprises transformation. At the Armed Forces Institute of Pathology, Rappaport classified 253 cases of follicular lymphoma based on histologic pattern and clinical correlation. 2 Rappaport noted the favorable prognosis of follicular (nodular) architecture over diffuse, as well as the tendency of follicular lymphomas to progress into diffuse lymphomas, typically of the corresponding cell type. In agreement with these observations, HT is commonly interpreted as loss of follicular architecture and evolution toward a larger, less differentiated cell type such as diffuse mixed or diffuse large-cell lymphoma (Table 1) . Occasionally, follicular small cleaved cell (grade I) or follicular mixed small and large-cell histology (grade II) that progresses to follicular large cell (grade III) is included. Here the change in histology is solely an increase in proportion of large to small cells and does not involve a loss of nodular architecture. In an attempt to make studies on HT uniform, more recent series have excluded follicular large cell as well as diffuse small cell lymphomas. This makes for ease of interpretation of study outcomes, but does leave unanswered clinical issues regarding these subtypes.
Incidence
The reported incidence of HT ranges from 10 to 70%. [4] [5] [6] [7] [8] It is difficult to determine the true incidence as it depends not only on the definition of HT, but also on the frequency and sites of biopsy, duration of follow-up, and the population considered at risk. Optimally, a change in the clinical nature of disease leads to a repeat lymph node biopsy that reveals a progression from follicular to diffuse histology of a higher grade. However, in some instances of clinical progression, no sites are amenable to biopsy, and in the event of only extranodal involvement a diagnosis must be made solely from cytologic features. In addition, although follicular lymphoma is often disseminated, HT can occur at a single node and thus a repeat biopsy may fail to reveal transformed disease.
Bastion et al
5 reviewed 220 patients with follicular lymphoma and identified 52 patients with transformation (34 by histology, 13 by cytology, and five on clinical grounds). These represented 24% of all 220 patients with follicular lymphoma but 37% of those with disease progression, 54% in first relapse, and 40% in second relapse. With a median follow-up of 9 years, the probability of transformation was calculated to be 22% at 5 years and 31% at 10 years. Among those with relapse, the risk of HT was calculated as 33% at 5 years and 51% at 10 years. After 6 years, a tendency toward a plateau in the incidence of HT was observed. However, cases of HT have been reported more than 10 years from diagnosis, suggesting an increased risk of HT with time and number of relapses. [4] [5] [6] [7] Another method to quantify the incidence of HT is with autopsy data. Garvin et al 8 classified histology at autopsy of 192 cases and compared it to that at initial diagnosis. Of the 56 patients with nodular disease at diagnosis, 30% had evidence of HT on repeat biopsy at 6 months following diagnosis and 68% had diffuse architecture at autopsy. Horning demonstrated a variation in the incidence of HT according to the population at risk by calculating an incidence of 12% in the initial evaluable group, 20% in patients requiring treatment of symptomatic disease, and 44% in patients in whom a repeat biopsy was obtained because of clinically progressive disease. 9 
Mechanism of transformation
The mechanism of HT in follicular lymphoma remains unknown, although a variety of molecular rearrangements have been implicated ( Table 2 ). The translocation t(14;18)(q32;q21) has been detected in 75-85% of follicular lymphomas. 10, 11 This event places the B-cell lymphoma-2 (BCL2) proto-oncogene in juxtaposition to the Ig heavy chain gene locus. The result is overexpression of the BCL2 gene product, which contributes to prolonged cell survival by blocking apoptosis. Defective cell suicide, by endowing neoplastic cells with a survival advantage, plays a role in the evolution of more aggressive derivatives, metastasis, and resistance to cytotoxic therapy. 12 It has been proposed that follicular lymphomas which undergo HT retain the t(14;18) translocation and acquire secondary cytogenetic abnormalities. 13 For example, the MYC oncogene, located on chromosome 8q24, has been reported to occur along with the BCL2 translocation in several case reports of transformed lymphomas.
14, 15 Yano et al 15 confirmed BCL2 rearrangements in 51 of 58 control patients with follicular lymphomas and 36 of 38 patients with transformed lymphoma. However, MYC rearrangements were detected in only three of the 38 (8%) transformed lymphoma samples. Others have implicated p53 mutations in HT. 16, 17 Additional chromosomal abnormalities reported with HT include deletions at chromosome 9p21 involving p16 and p15, amplification of chromosome 13, mutations at 6q27, and rearrangements at the BCL6 loci at 3q27 and the BCL3 loci at 17q22. 15, [18] [19] [20] [21] A microarray analysis of B-cell lymphoma lines with the translocation t(14;18) yielded 137 genes differentially expressed (68 genes were upregulated, 69 genes were downregulated), with 20% having no known function. 22 Lossos et al 23 compared gene expression profiles between transformed diffuse large-cell lymphomas and antecedent follicular lymphomas. Two gene-expression profiles were associated with transformation; interestingly, one with increased c-myc expression and the other with decreased expression.
Cohen et al 24 raise the issue of the role that chemotherapy drugs may play a role in transformation. They reported nine patients with indolent lymphomas in whom transformation to large-cell lymphomas occurred shortly after initiation of regimens-containing fludarabine and rituximab. Early studies proposed chemotherapy and radiation as potential factors in transformation. 6, 8, [25] [26] [27] Arguing against the contribution of chemotherapy drugs to HT is Horning's data that showed similar rates of trans-formation for treated and initially untreated follicular lymphoma. 9 
Risk factors for transformation
Acker et al 25 reviewed 22 patients with HT and was unable to identify any specific risk factors predictive of transformation. Likewise, Oviatt et al 5 studied 13 patients with HT, and neither age, gender, stage, visceral sites of disease, nor symptoms at presentation was predictive of subsequent transformation. In contrast, Bastion et al 5 identified lack of CR after initial therapy, low serum albumin, and b 2 -microglobulin 43 mg/l at diagnosis as predictive factors for HT in a group of 52 patients with HT.
Prognosis
The prognosis of HT is uniformly poor. The NCI data reported by Hubbard et al 7 gave a median overall survival (OS) from repeat biopsy for progressive disease of 11 months for HT vs 77 months without HT; OS from initial diagnosis was 48 months and 92 months for HT and without HT, respectively. The Vanderbilt data yielded a median OS from time of rebiopsy of 2.5 months for HT vs 37.5 months for patients without HT. 26 OS from initial diagnosis was similar to the NCI data, with 56.5 months for patients with HT and 89.2 months without HT.
There appear to be subsets of patients with HT who have significantly improved survival (Table 3 ). In the NCI analysis, median OS of patients achieving a CR with salvage chemotherapy after HT was 41 months, compared to 4 months for those who did not achieve a CR. 7 Similarly, the Stanford data showed a median OS of 81 months for patients who achieved a CR with therapy via either a doxorubicin-containing regimen, radiation therapy, surgery, or monoclonal antibody treatment, compared with 22 months for the entire group. 4 Patients with limited stage disease were more likely to achieve a CR with treatment compared with those with advanced disease (60 vs 20%) and have prolonged survival (108 vs 18 months). Survival was also longer for those patients not requiring treatment prior to HT, but this too is probably a measure of disease extent. Improved survival after transformation has also been associated with a previous CR and, at time of transformation, normal lactate dehydrogenase (LDH), lack of bone marrow involvement, no B symptoms, stages I-III disease, responsiveness to salvage treatment, and treatment with a CHOP (cyclophosphamide, adriamycin, vincristine, prednisone)-like regimen. 5 
Treatment of transformed lymphoma

Traditional chemotherapy
There are no randomized trials comparing various chemotherapy regimens in the treatment of transformed lymphoma. Still, there is something to be learned by extrapolating the data from case series and comparing outcomes of treatment for follicular lymphoma, transformed lymphoma, and de novo diffuse large-cell lymphoma. Follicular lymphoma typically follows an indolent course and has, with standard therapies, a median survival from diagnosis of 7-10 years. 28 HT appears to alter this clinical course, despite combination chemotherapy. For example, among the 52 patients with HT in Bastion's series, 30 were treated with a CHOP-like regimen, 20 with a regimen that did not include an anthracycline, and two received no treatment. 5 As a group the median OS was 7 months, with 20% alive at 3 years. Of patients treated with CHOP-like regimens, there were 19 responders (of whom seven went on to autologous transplant) with a median OS of 12 months and 3279% alive at 3 years. Patients who were either not treated with an anthracycline or did not receive any chemotherapy had a median OS of only 4 months with 574% alive at 3 years. Statistical analysis showed survival after transformation to be longer with CHOP-like chemotherapy.
Armitage et al 29 compared outcomes for chemotherapy for 15 patients with HT to treatment outcomes for de novo diffuse large-cell lymphoma. Disease-free survival (DFS) was significantly worse for the patients with HT compared to patients with de novo diffuse large-cell lymphoma, and no patient with HT achieved long-term DFS.
Monoclonal antibodies and radioimmunoconjugates
Monoclonal antibodies and radioimmunoconjugates are novel therapies that may have promise in the management of transformed lymphoma. A randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan (Zevalin) vs the unlabeled monoclonal antibody, rituximab (Rituxan), in patients with relapsed or refractory low-grade, follicular, or transformed B-cell (CD20 + ) non-Hodgkin's lymphoma (NHL) was reported by Witzig et al. 30 For all patients, the overall response rate (ORR) was 80% for Zevalin vs 56% for the Rituxan group (P ¼ 0.002). Of the 143 patients 32 evaluated the dose, efficacy, and safety of Bexxar in 47 relapsed/refractory low-grade and transformed low-grade NHL. Similar results were observed in patients with low-grade lymphoma and transformed low-grade lymphoma. The fact that phase II trials recruit heavily pretreated patients may actually under represent the response of patients with transformed lymphoma to immunotherapy. On the other hand, all patients in these trials, including Witzig's randomized study, were required to have no more than 25% of the intratrabecular marrow space involved with lymphoma, and thus were a selected group with perhaps a better prognosis. Further experience is required to determine the role that monoclonal antibodies and radioimmunoconjugates will have in the therapeutic armamentarium. Studies are underway incorporating Rituxan and radioimmunoconjugates into treatment regimens for follicular and transformed lymphoma in both the nontransplant and transplant setting. 33 For follicular lymphoma, two clinical trials utilizing Rituxan as single agent treatment or in combination with CHOP chemotherapy have shown eradication of the bcl-2 [t(14;18)] translocation from blood and bone marrow (BM). 34, 35 These molecular responses were associated with high clinical response rates and suggest a prolonged progression-free survival. It is unknown if a similar effect will be seen in transformed lymphoma.
Autologous transplantation
There have been several studies investigating intensive chemotherapy regimens with autologous stem cell support in an effort to improve response and survival [36] [37] [38] [39] [40] [41] [42] [43] [44] (Table 4 ). In 1989, Schouten et al 38 reported 10 patients who had undergone autologous transplantation for HT at the University of Nebraska. The outcomes were discouraging with a high early treatment-related mortality (TRM) of 70% and only one of 10 patients remained alive in CR at 99 days. However, only half of the patients had proven chemosensitive disease, with the others either resistant to chemotherapy or had not been tested.
Subsequent studies have selected for a more chemosensitive patient population. Freedman et al 37 Though Berglund et al 41 included only 11 patients with HT and chemosensitive disease, the follow-up time was the longest of all reported series at 74 months. Outcomes for the patients with HT were not given separately from the entire group, but it was noted that the OS (81%) and DFS (72%) did not differ. Of the seven patients who experienced disease relapse, one did not recur until 92 months post-transplant. Additionally, no significant difference in survival was found with respect to age, number of chemotherapeutic regimens or relapses, LDH at transplant, gender, conditioning regimen, or purging. Of note, patients treated with total body irradiation (TBI) fared worse in terms of OS and late sequelae. Of 92 patients with chemosensitive follicular lymphoma who underwent transplantation with purged autologous BM or PBSC cells at Stanford, 17 had HT. 42 In the report by Cao et al, approximately half 43 analyzed 35 patients with chemosensitive disease who received highdose therapy and TBI followed by unpurged BM or PBSC rescue. At a median follow-up of 54 months, 19 patients had died (from TRM in seven, myelodysplastic syndrome in three, and progressive lymphoma in nine), resulting in an OS of 37% and DFS of 36% at 5 years. Contributing to the high TRM were five patients over the age of 60 who all died. Williams et al 6 reported 50 patients with chemosensitive transformed follicular lymphoma who underwent autologous transplantation and compared their outcomes with 200 case-matched low-grade lymphoma patients and 200 case-matched patients with de novo high-or intermediate-grade lymphoma undergoing the same procedure. For the patients with transformed lymphoma, OS and DFS were 51 and 30% at 5 years, respectively. Median DFS time was 13 months. An increased LDH level at transformation was identified as the only adverse significant predictor of DFS on multivariate analysis. There was no significant difference in OS or DFS in case-matched comparison to low-grade follicular lymphoma or de novo high-or intermediate-grade lymphoma. No difference in mortality was found for patients who received PBSC vs BM. All nine patients with early TRM had received TBI. The authors concluded that high-dose therapy and autologous transplantation may benefit specific patients with residual chemosensitive disease after salvage chemotherapy, a group that did poorly with traditional chemotherapy in the series reported by Yuen. 4 Finally, Le Gouill et al 44 proposed tandem high-dose therapy followed by autologous stem cell transplantation for refractory or relapsed high-grade NHL and included 3 patients with transformed follicular lymphoma in a pilot study. All 3 patients survived the regimen and were alive without relapse at 32.5, 44.5, and 54.7 months.
For the most part, OS and DFS following autologous transplantation range from 30 to 60% at 4-5 years. These results are put in context by comparison to outcomes with autologous transplantation for follicular lymphoma and diffuse large-cell lymphoma. Hunault-Berger's review of intensive treatment for follicular lymphoma, with 14 trials summarized, showed that for progressing/relapsing follicular lymphoma, OS ranged from 33% at 3 years to 81% at 7 years, and DFS ranged from 18% at 2 years to 72% at 7 years. 50 The patients represented in trials of autologous transplantation for progressing/relapsing FL are similar to patients with transformed lymphoma in terms of prior chemotherapy and extent of disease; not surprisingly, the results for autologous transplantation are similar. The largest randomized trial of autologous transplantation for patients with diffuse aggressive NHL is the PARMA trial. 51 With a median follow-up of 63 months, the transplant group had an OS of 53% and 5 year event-free survival of 46%. Again, these results are comparable to outcomes for transformed lymphoma and the case-matched comparisons performed by Williams et al. 6 As noted above, some studies incorporated purging of stem cells with monoclonal antibodies in hopes of removing all malignant cells. It remains unclear whether or not purging improves outcomes. [45] [46] [47] [48] Purging may not eliminate t (14;18) , but, the significance of its continued presence is unknown. 38, 49 Early TRM, ranging from 5 to 20% in the reported series, is most likely reflective of a middle-aged patient group with advanced stage disease, who have been heavily pretreated. In the majority of the reported series, patients had undergone 1-3 salvage regimens in order to achieve a minimal disease state at time of transplant. Not surprisingly, much of the TRM was secondary to infectious complications. In addition to TRM, outcomes from autologous transplantation are adversely affected by a 2-15% incidence of second malignancies, predominantly MDS and AML. 9, [38] [39] [40] [41] Though the small absolute numbers precluded analysis, several investigators proposed the cause to be the cumulative risk of alkylating agents and TBI. With the 3 cases of MDS in Berglund's series occurring at 4, 5, and 7 years post-transplant, the concern for increasing incidence of MDS/AML with longer follow-up time arises. 41 The cumulative incidence of MDS/AML following stem cell transplants for lymphoma has been reported to be approximately 15% at 5-10 years post-transplant, similar to that following transplantation for HT. 52, 53 In summary, the trials of autologous transplantation for transformed lymphoma suggest a prolonged survival with outcomes comparable to relapsed follicular lymphoma and de novo diffuse large-cell lymphoma. However, the total number of patients reported overall is very small, and most likely reflects a very select group of patients with good prognostic factors and whose disease remained responsive enough to allow transplantation to be performed. Regardless, it appears that patients with chemosensitive, transformed lymphoma should be strongly considered for high-dose therapy with stem cell support. Obstacles to be overcome include reduction of early TRM and posttransplant relapse, as well as the incidence of secondary malignancies.
Allogeneic transplant
There are no published studies of allogeneic transplantation in transformed lymphoma. However, allogeneic transplantation for follicular lymphoma, while associated with an increased TRM compared with autologous transplantation, results in a significantly decreased relapse rate, providing support for a graft-versus-lymphoma (GVL) effect. 54, 55 Nonmyeloablative conditioning regimens seek to capitalize on the GVL effect while decreasing TRM. 56 Whether similar results will be noted in patients with HT has yet to be determined.
Conclusion and future directions
Despite over 50 years of medical experience and breakthroughs since the phenomenon of HT in follicular lymphoma was described, HT remains a significant risk for patients and the overall prognosis remains poor. The application of microarray gene analysis may lead to a better understanding of the molecular events underlying HT, and ultimately the development of a prognostic index that clinicians may use to stratify patients for therapy. Until then, autologous transplantation should be considered the standard of care for patients with chemosensitive disease, as it appears to be curative for approximately one-third of such patients. Unfortunately, post-transplant relapse as well as the development of myelodysplastic syndrome further limits the curative potential of autologous transplantation. Clearly, alternative therapies are required for patients with chemoresistant disease or other high-risk features. The observed decreased risk of relapse with allogeneic transplantation in follicular lymphoma suggests one strategy for improving outcomes, but only if the increased TRM associated with allogeneic transplantation can be reduced, perhaps via incorporation of nonmyeloablative conditioning regimens. Enticing to the clinical researcher is the field of immunotherapy, and one can envision strategies of combining radioimmunoconjugates with other monoclonal antibodies, cytotoxic agents, autologous stem cell support, or allogeneic effector cells. As knowledge of the molecular mechanisms underlying HT increases, hopefully novel agents can be identified for both follicular lymphoma and transformed disease. Future studies implementing these novel approaches, alone and in combination, may ultimately eliminate an Achilles' heel of NHL.
